Clarence Moore, PharmD, BCPS, BCOP, assistant professor at Shenandoah University in Ashburn, Virginia, discussed the potential complications for patients with beta thalassemia associated with iron overload and the significance of chelation therapy.
Transcript
Can you discuss the seriousness of iron overload as a result of blood transfusions in patients with beta thalassemia and the role of chelation therapy?
When you look at the iron overload that we see with these individuals that have beta thalassemia, it's probably one of the biggest issues that we'll tend to see because of the fact that iron overload can deposit in certain organs, whether that be the heart, the pancreas, or the liver—we can start to see some organ dysfunction. Chelation therapy is huge. Being able to utilize chelation therapy in the pediatric setting, I think has been monumental in the prevention of this iron overload as well as the prolonging of life.
New Study Finds Risk Groups, Outpatient Care Barriers in Chronic Liver Disease
November 20th 2024Patients with chronic liver disease who were unable to establish care were 85% more likely to require recurrent hospitalizations. This group included a disproportionate number of women and individuals with physical limitations affecting their health.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
OS Better With Belantamab Mafodotin Triplet vs Daratumumab in R/R MM
November 19th 2024The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R MM).
Read More